Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Practical handling follows from those properties. Bulk material is best divided into single-use portions soon after receipt, because each thaw exposes the whole container to moisture and temperature cycling. Vials should be allowed to reach room temperature before opening to prevent condensation on the powder. Low-binding plasticware reduces loss of dilute solutions, and sterile filtration is used when a preparation must remain free of microbial growth. Records of batch number, reconstitution date and storage history are what allow a later analytical result to be interpreted meaningfully.
Identity and purity of Semax are established mainly by reversed-phase high-performance liquid chromatography coupled with mass spectrometry. The chromatographic trace gives a purity estimate as a percentage of total peak area, while electrospray or matrix-assisted laser desorption ionization confirms the molecular mass against the calculated value. Amino acid analysis and sequence-specific fragmentation provide further confirmation when a supplier's chain of custody is unclear. Vendors frequently quote a purity figure without stating the detection wavelength or the integration method, which limits how far one number can be compared with another.
Stability depends heavily on physical state. Lyophilized powder held dry, cold and dark retains its content over long periods, whereas dissolved peptide begins to change within days at room temperature. The most cited degradation route is oxidation of the methionine residue, which converts the peptide to a sulfoxide form that elutes differently on chromatography. Hydrolysis of amide bonds and adsorption onto container walls contribute smaller losses. Buffers that exclude oxygen from the headspace slow the oxidation pathway, but no single condition prevents all change indefinitely.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Radioactive decay results in a reduction of summed rest mass, once the released energy (the disintegration energy) has escaped in some way. Although decay energy is sometimes defined as associated with the difference between the mass of the parent nuclide products and the mass of the decay products, this is true only of rest mass measurements, where some energy has been removed from the product system. This is true because the decay energy must always carry mass with it, wherever it appears (see mass in special relativity) according to the formula E = mc2. The decay energy is initially released as the energy of emitted photons plus the kinetic energy of massive emitted particles (that is, particles that have rest mass). If these particles come to thermal equilibrium with their surroundings and photons are absorbed, then the decay energy is transformed to thermal energy, which retains its mass. Decay energy, therefore, remains associated with a certain measure of the mass of the decay system, called invariant mass, which does not change during the decay, even though the energy of decay is distributed among decay particles. The energy of photons, the kinetic energy of emitted particles, and, later, the thermal energy of the surrounding matter, all contribute to the invariant mass of the system. Thus, while the sum of the rest masses of the particles is not conserved in radioactive decay, the system mass and system invariant mass (and also the system total energy) is conserved throughout any decay process.
Many of the medications used in feminizing hormone therapy, such as estradiol, cyproterone acetate, and bicalutamide, are substrates of CYP3A4 and other cytochrome P450 enzymes. As a result, inducers of CYP3A4 and other cytochrome P450 enzymes, such as carbamazepine, phenobarbital, phenytoin, rifampin, rifampicin, and St. John's wort, among others, may decrease circulating levels of these medications and thereby decrease their effects. Conversely, inhibitors of CYP3A4 and other cytochrome P450 enzymes, such as cimetidine, clotrimazole, grapefruit juice, itraconazole, ketoconazole, and ritonavir, among others, may increase circulating levels of these medications and thereby increase their effects. The concomitant use of a cytochrome P450 inducer or inhibitor with feminizing hormone therapy may necessitate medication dosage adjustments.
Bromley forms part of the Bromley and Biggin Hill Parliament constituency. The current MP is Peter Fortune. Thomas Turrell is the London Assembly member for the Bexley and Bromley constituency, in which the town is located. This post was previously held by Fortune. Bromley's most prominent MP was the former Conservative prime minister, Harold Macmillan. Bromley is part of the Bromley Town ward for elections to Bromley London Borough Council.
== Substrate specificity == APX enzymes show high specificity for ascorbate as an electron donor, but most APXs will also oxidise other organic substrates that are more characteristic of the class III peroxidases (such as horseradish peroxidase), in some cases at rates comparable to that of ascorbate itself. This means that defining an enzyme as an APX is not straightforward, but is usually applied when the specific activity for ascorbate is higher than that for other substrates. Some proteins from the APX family lack the ascorbate-binding amino acid residues suggesting that they might oxidize other molecules than ascorbate.
=== Penicillin === Penicillin is a group of antibiotics that have been effective against many bacterial infections. It attacks bacteria by targeting and inhibiting the transpeptidase that catalyzes the cross-linking of the amino sugars in peptidoglycan. However, pseudopeptidoglycan contains different amino sugars, and therefore, a different catalysis enzyme is used. The different amino acids cause antibiotics, that target cell walls like penicillin, to be ineffective against pseudopeptidoglycan.
Sources: en.wikipedia.org
== Pharmacology == The drug potentiates the tropomyosin receptor kinases TrkA, TrkB, and TrkC with EC50Tooltip half-maximal effective concentration values of 382 nM, 295 nM, and ~330 nM, respectively. As a positive allosteric modulator of TrkA and TrkB, ACD856 potentiates the effects of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). In addition to the tropomyosin receptor kinases, ACD856 is also a similarly potent positive allosteric modulator of certain other receptor tyrosine kinases, including the insulin-like growth factor 1 receptor (IGF1R) and the fibroblast growth factor receptor 1 (FGFR1). However, its efficacies at the IGF1R and FGFR1 were much lower than at the TrkA, TrkB, and TrkC. In animals, ACD856 has been found to reverse scopolamine- and dizocilpine (MK-801)-induced memory impairment, to improve age-related memory deficits, and to have sustained antidepressant-like activity. It has also been reported to possess neuroprotective properties. In humans, the drug has been shown to cross the blood–brain barrier and to induce dose-dependent changes in electroencephalogram parameters. No significant tolerability or safety concerns have been identified in preclinical research or phase 1 clinical trials. The drug's clinical pharmacokinetics have been characterized and its elimination half-life is approximately 19 hours.
1% (w/w) Nonidet P-40 (NP-40) 1% (w/v) sodium deoxycholate 0.1% (w/v) SDS 0.15 M NaCl 0.01 M sodium phosphate, pH 7.2 2 mM EDTA 50 mM sodium fluoride (NaF) 0.2 mM fresh sodium orthovanadate (Na3VO4.2H2O, it has phosphatase inhibitor function because it mimics phosphate) 100 U/ml protease inhibitor, such as aprotinin
R = universal gas constant m = number of occupied lattice sites per molecule (for polymer solutions m1 is approximately equal to the degree of polymerization and m2=1) φ = volume fraction of the polymer and the solvent, respectively χ = interaction parameter A consequence of the Flory-Huggins theory is, for instance, that the UCST (if it exists) increases and shifts into the solvent-rich region when the molar mass of the polymer increases. Whether a polymer shows LCST and/or UCST behavior can be derived from the temperature-dependence of the interaction parameter (see figure). The interaction parameter not only comprises enthalpic contributions but also the non-ideal entropy of mixing, which again consists of many individual contributions (e.g., the strong hydrophobic effect in aqueous solutions). For these reasons, classical Flory-Huggins theory cannot provide much insight into the molecular origin of miscibility gaps.
In addition, a direct joining of ribose, a nucleobase, and phosphate to make a ribonucleotide (the building block of RNA) is not currently chemically feasible. Alternative prebiotic mechanisms have been proposed including cyanosulfidic prebiotic chemistries.
There, they joined former presidents Bill Clinton and Jimmy Carter. Alongside the 2014 United States–Africa Leaders Summit, Bush, Michelle Obama, the State Department, and the George W. Bush Institute hosted a daylong forum on education and health with the spouses of the African leaders attending the summit. Bush urged African leaders to avoid discriminatory laws that make the treatment of HIV/AIDS more difficult. On November 2, Bush spoke at an event to 200 business and civic leaders at the George W. Bush Presidential Library and Museum to raise awareness of the upcoming Museum of the Bible in Washington, D.C. On November 11, Bush published a biography of his father titled 41: A Portrait of My Father. In an interview published by Israel Hayom magazine on June 12, 2015, Bush said that "boots on the ground" would be needed to defeat the Islamic State of Iraq and the Levant (ISIS). He added that people had said during his presidency that he should withdraw American troops from Iraq, but he chose the opposite, sending 30,000 more troops to defeat Al Qaeda in Iraq, and that they indeed were defeated. Bush was also asked about Iran but declined to answer, stating that any answer he gives would be interpreted as undermining Obama. During the early stages of the 2016 Republican presidential primaries, Bush spoke and campaigned for his brother Jeb Bush at a South Carolina rally. However, the party's nomination eventually went to Donald Trump, whom Bush refused to endorse. Furthermore, he did not attend the party's convention.
Sources: en.wikipedia.org
=== The renaissance: the hammerhead ribozyme and the group I intron: P4-6 === For a considerable time following the first tRNA structures, the field of RNA structure did not dramatically advance. The ability to study an RNA structure depended upon the potential to isolate the RNA target. This proved limiting to the field for many years, in part because other known targets—i.e., the ribosome—were significantly more difficult to isolate and crystallize. Further, because other interesting RNA targets had simply not been identified, or were not sufficiently understood to be deemed interesting, there was simply a lack of things to study structurally. As such, for some twenty years following the original publication of the tRNAPHE structure, the structures of only a handful of other RNA targets were solved, with almost all of these belonging to the transfer RNA family. This unfortunate lack of scope would eventually be overcome largely because of two major advancements in nucleic acid research: the identification of ribozymes, and the ability to produce them via in vitro transcription. Subsequent to Tom Cech's publication implicating the Tetrahymena group I intron as an autocatalytic ribozyme, and Sidney Altman's report of catalysis by ribonuclease P RNA, several other catalytic RNAs were identified in the late 1980s, including the hammerhead ribozyme. In 1994, McKay et al. published the structure of a 'hammerhead RNA-DNA ribozyme-inhibitor complex' at 2.6 Ångström resolution, in which the autocatalytic activity of the ribozyme was disrupted via binding to a DNA substrate.
=== Thin layer chromatography === Thin layer chromatography (TLC) is a type of chromatography technique that is used characterized or separate lipids. The lipids are separated based on the polarity of the head groups or hydrophilic region, not the hydrophobic region. Certain stains like iodine can be used to label the lipids but will sometimes destroy the lipids. This process can also be used to determine whether or not lipids have denatured. For example, originally a TLC analysis shows the presence of two lipids. One week later the same sample is reanalyzed but shows the presence of more lipids, which indicates the lipid has denatured.
Formylation of benzene rings can be achieved via the Gattermann reaction and Gattermann-Koch reaction. These involve strong acid catalysis and proceed in a manner similar to the Friedel–Crafts reaction.
Centrifugal partition chromatography requires only a biphasic mixture of solvents, so by varying the constitution of the solvent system it is possible to tune the partition coefficients of different compounds so that separation is guaranteed by the high selectivity.
Heavy metals, such as lead (Pb), manganese (Mn), iron (Fe), copper (Cu), mercury (Hg), aluminum (Al), bismuth (Bi), zinc (Zn) and selenium (Se) have been linked to PD. They cross the blood-brain barrier, and can disrupt cellular mechanisms, leading to neuroinflammation, oxidative stress, and mitochondrial dysfunction. While some metals like manganese are needed in small amounts for healthy cellular functioning, others like lead are considered toxic at any level of exposure. Lead is considered "one of the most harmful pollutants for human health". Lead-based paint in the United States was banned in 1978. Tetraethyllead was added to gasoline in the United States until the 1990s. As a result, lead was released into the air as part of vehicle exhaust. Lead pipes continue to introduce lead contaminants into water supplies and household water. Following exposure, lead is absorbed into the body where it accumulates in blood, bones, teeth, and soft tissues such as the brain, liver, and kidney. Lead remains in the body and can cause both acute and chronic lead poisoning. Lead is known to damage the central nervous system in a variety of ways, with children being particularly vulnerable. Population studies suggest that higher levels of lead in bone and blood are associated with a higher risk of PD. Lead may be linked to PD through oxidative stress and mitochondrial dysfunction. Regulatory actions and public health measures have contributed to a substantial decrease in the levels of lead exposure measured in the US population since the 1970s.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.